Home

Mark Sullivan

CIK 1331843 · Chief Legal Officer · last filed 2026-09-14

Mark Sullivan is a Chief Legal Officer who has filed 36 SEC Form 4 insider transactions across 4 companies since 2011. The most recent filing, for DFTX, was dated Sep 14, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $19.7M across reported positions. 6 SEC filings were submitted jointly with MedQuist Holdings Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$19.73M

Companies

4

Total Filings

36

Lifetime Open-Market Net

-$1.55M

Filer Profile

Reported Address
1000 BISHOPS GATE BOULEVARD
SUITE 300
MOUNT LAUREL, NJ 08054
Related Filers
MedQuist Holdings Inc. — 6 joint filings, latest 2012-01-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DFTX Chief Legal Officer 508,279 $38.81 $19.73M -$783.4K 6 2026-09-14
Definium Therapeutics, Inc. (MNMD) Delisted Chief Legal Officer 282,576 $15.00 $4.24M -$569.9K 10 2025-12-29
Carisma Therapeutics Inc. (SESN) Delisted General Counsel & Secretary 19,186 $12.58 $241.3K -$152.1K 6 2023-03-06
MModal Inc. (MEDH) Delisted Gen Counsel, CCO & Secretary 39,268 — — -$43.7K 5 2012-01-04

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-14 DFTX Grant (A) +125,000 $0 EDGAR
2026-08-12 DFTX Grant (A) +62,500 $0 EDGAR
2026-06-26 DFTX Sell (S) −13,008 -$585.8K EDGAR
2026-06-25 DFTX Notice (144) −13,008 -$548.0K EDGAR
2026-06-22 DFTX Grant (A) +62,500 $0 EDGAR
2026-03-26 DFTX Sell (S) −10,702 -$197.7K EDGAR
2026-03-25 DFTX Notice (144) −10,702 -$197.7K EDGAR
2026-02-05 DFTX Grant (A) +125,000 $0 EDGAR
2025-12-29 Definium Therapeutics, Inc. (MNMD) Delisted Sell (S) −11,276 -$148.2K EDGAR
2025-12-29 DFTX Notice (144) −11,276 -$148.2K EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.